Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02849080 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 504
- Enrollment target
NCT02849080 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 504 participants.
The verdict
NCT02849080, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 504 participants
- Enrollment target
Study Summary
This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus.
Interventions
- DRUG semaglutide
- DRUG sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2016-09-20 |
| Est. Completion | 2019-03-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02849080
The ClinicalTrials.gov registry entry for NCT02849080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which semaglutide is the first listed.
NCT02849080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02849080 about?
NCT02849080 is a clinical study titled "Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.". This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT02849080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2016-09-20. Estimated completion is 2019-03-27.
What interventions are being tested in trial NCT02849080?
The interventions under investigation include: semaglutide (DRUG), sitagliptin (DRUG).
Who is sponsoring clinical trial NCT02849080?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.